Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial

IMPORTANCE: In the pivotal Bevacizumab-Avastin Adjuvant (AVANT) trial, patients with high-risk stage II colon cancer (CC) had 5-year and 10-year overall survival (OS) rates of 88% and 75%, respectively, with adjuvant fluorouracil and oxaliplatin–based chemotherapy; however, the trial did not demonst...

Descripción completa

Detalles Bibliográficos
Autores principales: Chibaudel, Benoist, Henriques, Julie, Rakez, Manel, Brenner, Baruch, Kim, Tae Won, Martinez-Villacampa, Mercedes, Gallego-Plazas, Javier, Cervantes, Andres, Shim, Katharine, Jonker, Derek, Guerin-Meyer, Veronique, Mineur, Laurent, Banzi, Chiara, Dewdney, Alice, Dejthevaporn, Thitiya, Bloemendal, Haiko J., Roth, Arnaud, Moehler, Markus, Aranda, Enrique, Van Cutsem, Eric, Tabernero, Josep, Schmoll, Hans-Joachim, Hoff, Paulo M., André, Thierry, de Gramont, Aimery
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573695/
https://www.ncbi.nlm.nih.gov/pubmed/33074326
http://dx.doi.org/10.1001/jamanetworkopen.2020.20425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573695/
https://www.ncbi.nlm.nih.gov/pubmed/33074326
http://dx.doi.org/10.1001/jamanetworkopen.2020.20425

Ejemplares similares